0546 GMT - Sandoz's sales miss is disappointing but prospects should improve in the second half due to a wave of upcoming biosimilar launches, RBC Capital Markets analysts say in a note. The Swiss generics maker stuck to its 2025 outlook, and confirmed it can absorb its current tariff exposure, despite 1Q sales that missed expectations on weaker demand in North America, they say. Sandoz has called out a lower private label pricing for its autoimmune disease treatment adalimumab, which will likely be the focus of analysts and investors, they add. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 01:46 ET (05:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。